Skip to main content

Table 3 Distribution after recurrent stroke

From: Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

  

mRS state before recurrent

Reference

mRS 0

mRS 1

mRS 2

mRS 3

mRS 4

mRS 5

 

Post-recurrent mRS state

mRS 0

17.82%

     

[24]

mRS 1

22.77%

40.59%

    

mRS 2

8.91%

8.91%

49.50%

   

mRS 3

11.88%

11.88%

11.88%

61.38%

  

mRS 4

13.86%

13.86%

13.86%

13.86%

75.24%

 

mRS 5

6.93%

6.93%

6.93%

6.93%

6.93%

82.17%

  1. mRS modified Rankin Scale